Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

620.66
Delayed Data
As of Aug 07
 -0.55 / -0.09%
Today’s Change
271.37
Today|||52-Week Range
664.64
+65.30%
Year-to-Date
Merck to Begin Pivotal COVID-19 Antiviral Studies in September
Jul 31 / MotleyFool.com - Paid Partner Content
Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players
Jul 28 / Seeking Alpha - Paid Partner Content
Regeneron teams up with BioNTech in melanoma
Jul 31 / Seeking Alpha - Paid Partner Content
Biotech Bonanza - Second Half Outlook
Jul 28 / Seeking Alpha - Paid Partner Content
Roche's Rheumatoid Arthritis Drug Fails to Help COVID-19 Patients (Again)
Jul 29 / MotleyFool.com - Paid Partner Content
Will Regeneron Help Win the Fight Against COVID-19?
Jul 28 / MotleyFool.com - Paid Partner Content
Regeneron lands BARDA contract for Ebola cocktail
Jul 29 / Seeking Alpha - Paid Partner Content
 

Today’s Trading

Previous close621.21
Today’s open626.75
Day’s range614.76 - 627.00
Volume26,834
Average volume (3 months)1,215,784
Market cap$64.7B
Data as of 4:00pm ET, 08/07/2020

Growth & Valuation

Earnings growth (last year)-14.46%
Earnings growth (this year)+10.36%
Earnings growth (next 5 years)+12.00%
Revenue growth (last year)+17.18%
P/E ratio24.1
Price/Sales5.47
Price/Book6.29

Competitors

----
----
TAKTakeda Pharmaceutica...-0.04-0.22%
VRTXVertex Pharmaceutica...-0.34-0.12%
Data as of 4:00pm ET, 08/07/2020

Financials

Next reporting dateNovember 4, 2020
EPS forecast (this quarter)$7.26
Annual revenue (last year)$7.9B
Annual profit (last year)$2.1B
Net profit margin26.91%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Tarrytown, New York

Forecasts